Ziyan Zang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ziyan Zang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Hui Chang
College of Food Science, Southwest University, Chongqing 400715, China
4 shared publications - Hongxia Ni
College of Food Science, Southwest University, Chongqing 400715, People's Republic of China nhx990308@.swu.edu.cn
3 shared publications - Linhai Cao
Chongqing Municipal Health Commission Key Laboratory of Precise Orthopedics, Department of Orthopaedic Surgery, The Second Affiliated Hospital, Army Medical University, Chongqing 400038, China
3 shared publications - Xiaoxiao Gong
College of Food Science, Southwest University, Chongqing 400715, People's Republic of China zan181416010305@.swu.edu.cn
3 shared publications - Haoxin Fan
Southwest University
1 shared publication - Lin Huang
Southwest University
1 shared publication
Latest Publications
- 11 June 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 273 (Pt 1) , 133087
Resistant starch from yam: Preparation, nutrition, properties and applications in the food sector
- 11 June 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 273 (Pt 1) , 133087
Resistant starch from yam: Preparation, nutrition, properties and applications in the food sector
- 16 April 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 330, 118179
Chinese herbal medicine for the treatment of diabetic nephropathy: From clinical evidence to potential mechanisms
- 16 April 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 330, 118179
Chinese herbal medicine for the treatment of diabetic nephropathy: From clinical evidence to potential mechanisms
- 24 January 2024
- Published by Springer Nature in Drugs
- Vol. 84 (2) , 179-202
Chinese Herbal Medicines for Coronary Heart Disease: Clinical Evidence, Pharmacological Mechanisms, and the Interaction with Gut Microbiota
Coronary heart disease (CHD) is a common type of cardiovascular disease (CVD) that has been on the rise in terms of both incidence and mortality worldwide, presenting a significant threat to human health. An increasing body of studies has shown that traditional Chinese medicine (TCM), particularly Chinese herbal medicines (CHMs), can serve as an effective adjunctive therapy to enhance the efficacy of Western drugs in treating CHD due to their multiple targets and multiple pathways. In this article, we critically review data available on the potential therapeutic strategies of CHMs in the intervention of CHD from three perspectives: clinical evidence, pharmacological mechanisms, and the interaction with gut microbiota. We identified 20 CHMs used in clinical practice and it has been found that the total clinical effective rate of CHD patients improved on average by 17.78% with the intervention of these CHMs. Subsequently, six signaling pathways commonly used in treating CHD have been identified through an overview of potential pharmacological mechanisms of these 20 CHMs and the eight representative individual herbs selected from them. CHMs could also act on gut microbiota to intervene in CHD by modulating the composition of gut microbiota, reducing trimethylamine-N-oxide (TMAO) levels, increasing short-chain fatty acids (SCFAs), and maintaining appropriate bile acids (BAs). Thus, the therapeutic potential of CHMs for CHD is worthy of further study in view of the outcomes found in existing studies. Graphical Abstract
- 24 January 2024
- Published by Springer Nature in Drugs
- Vol. 84 (2) , 179-202
Chinese Herbal Medicines for Coronary Heart Disease: Clinical Evidence, Pharmacological Mechanisms, and the Interaction with Gut Microbiota
Coronary heart disease (CHD) is a common type of cardiovascular disease (CVD) that has been on the rise in terms of both incidence and mortality worldwide, presenting a significant threat to human health. An increasing body of studies has shown that traditional Chinese medicine (TCM), particularly Chinese herbal medicines (CHMs), can serve as an effective adjunctive therapy to enhance the efficacy of Western drugs in treating CHD due to their multiple targets and multiple pathways. In this article, we critically review data available on the potential therapeutic strategies of CHMs in the intervention of CHD from three perspectives: clinical evidence, pharmacological mechanisms, and the interaction with gut microbiota. We identified 20 CHMs used in clinical practice and it has been found that the total clinical effective rate of CHD patients improved on average by 17.78% with the intervention of these CHMs. Subsequently, six signaling pathways commonly used in treating CHD have been identified through an overview of potential pharmacological mechanisms of these 20 CHMs and the eight representative individual herbs selected from them. CHMs could also act on gut microbiota to intervene in CHD by modulating the composition of gut microbiota, reducing trimethylamine-N-oxide (TMAO) levels, increasing short-chain fatty acids (SCFAs), and maintaining appropriate bile acids (BAs). Thus, the therapeutic potential of CHMs for CHD is worthy of further study in view of the outcomes found in existing studies. Graphical Abstract